Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.


The bidding war for Spark Therapeutics

Spark Therapeutics logo.
Roche bought Spark for almost $5 billion. Photo courtesy of Spark Therapeutics

A new financial filing from Spark Therapeutics reveals that Roche low-balled its first offer to buy Spark for $70 a share, and then outbid three other pharmaceutical companies over several months before Spark agreed to Roche's offer of $114.50 per share — 64% higher than the original that resulted in the nearly $5 billion deal.

Between the lines: Spark's work centers around gene therapy, where mutated genes are replaced with new ones, and the filing shows its hemophilia research was the crown jewel that had everyone interested.

More stories loading.